Northern Trust Corp Viracta Therapeutics, Inc. Transaction History

Northern Trust Corp

$572 Billion
Q1 2024

A detailed history of Northern Trust Corp transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 38,190 shares of VIRX stock, worth $20,622. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,190

Previous 36,461 4.74%

Holding current value

$20,622

Previous $20,000 90.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$0.48 - $1.13 $829 - $1,953	1,729 Added 4.74%	38,190 $38,000
Q3 2023 Nov 13, 2023	SELL	$1.03 - $1.58 $2,111 - $3,239	-2,050 Reduced 5.32%	36,461 $37,000
Q2 2023 Aug 11, 2023	SELL	$0.89 - $2.13 $176 - $421	-198 Reduced 0.51%	38,511 $54,000
Q1 2023 May 15, 2023	BUY	$1.38 - $2.29 $1,916 - $3,180	1,389 Added 3.72%	38,709 $61,000
Q3 2022 Nov 14, 2022	BUY	$3.32 - $5.69 $12,592 - $21,582	3,793 Added 11.31%	37,320 $159,000

Q2 2022 Aug 12, 2022	SELL	$1.87 - $5.0 $458,335 - $1.23 Million	-245,099 Reduced 87.97%	33,527 $130,000
Q1 2022 May 13, 2022	SELL	$2.23 - $4.76 $33,151 - $70,762	-14,866 Reduced 5.07%	278,626 $1.33 Million
Q4 2021 Feb 08, 2022	SELL	$3.37 - $7.91 $28,995 - $68,057	-8,604 Reduced 2.85%	293,492 $1.07 Million
Q3 2021 Nov 15, 2021	SELL	$7.84 - $12.53 $88,231 - $141,012	-11,254 Reduced 3.59%	302,096 $2.42 Million
Q2 2021 Aug 13, 2021	BUY	$7.55 - $12.95 $2.27 Million - $3.89 Million	300,148 Added 2273.5%	313,350 $3.55 Million
Q1 2021 May 12, 2021	BUY	$7.58 - $18.67 $100,071 - $246,481	13,202 New	13,202 $122,000

Others Institutions Holding VIRX

# of Institutions

Shares Held

9.39M

Call Options Held

5.9K

Put Options Held

View Full List

About Viracta Therapeutics, Inc.

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $20.3M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

More about VIRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Viracta Therapeutics, Inc. Transaction History